combination therapy

Vale C, Lourenço IM, Jordan G, Golovaty I, Torres H, Moin T, Buysschaert M, Neves JS, Bergman M. Early combination therapy with SGLT2i and GLP-1[...]

Chow F, Lamoureux F, Moriceau G. Editorial: Developing next-generation therapeutics to defeat mutation-driven cancer. Front Immunol. 2024 Sep 26;15:1487952. doi: 10.3389/fimmu.2024.1487952. PMID: 39391312; PMCID: PMC11464455.

Chin KM, Channick R, Kim NH, MacDonald G, Ong R, Martin N, Senatore A, McLaughlin VV. Macitentan and Tadalafil Combination Therapy in Incident and Prevalent[...]

Gebremariam T, Alkhazraji S, Gu Y, Najvar LK, Borroto-Esoda K, Patterson TF, Filler SG, Wiederhold NP, Ibrahim AS. Ibrexafungerp is efficacious in a neutropenic murine[...]

Rotstein C, Lynch JP 3rd, Zhanel GG. Hospital-acquired bacterial pneumonia (HABP) and ventilator- associated bacterial pneumonia (VABP) in Canada:treatment update and the role of new[...]

Garon EB, Spira AI, Goldberg SB, Chaft JE, Papadimitrakopoulou V, Cascone T, Antonia SJ, Brahmer JR, Camidge DR, Powderly JD, Wozniak AJ, Felip E, Wu[...]

Masson R, Seivright J, Shih T, Bennett RG, Hogeling M, Shi VY, Hsiao JL. Trimethoprim/sulfamethoxazole and cephalexin combination therapy in hidradenitis suppurativa patients: A series[...]

Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in PD-(L)1-Monotherapy Pretreated, Advanced Non-Small Cell Lung Cancer: Results From a Phase 1b Clinical Trial

Wang X, Liu X, Hugo W, Si L, Shi H. Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments. Front Immunol. 2022[...]

Nel AE, Mei KC, Liao YP, Liu X. Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with[...]